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After each spliceosome cycle, the U4 and U6 snRNAs are released separately and are recycled to the
functional U4/U6 snRNP, requiring in the mammalian system the U6-specific RNA binding protein p110
(SART3). Its domain structure is made up of an extensive N-terminal domain with at least seven tetratri-
copeptide repeat (TPR) motifs, followed by two RNA recognition motifs (RRMs) and a highly conserved
C-terminal sequence of 10 amino acids. Here we demonstrate under in vitro recycling conditions that U6-p110
is an essential splicing factor. Recycling activity requires both the RRMs and the TPR domain but not the
highly conserved C-terminal sequence. For U6-specific RNA binding, the two RRMs with some flanking regions
are sufficient. Yeast two-hybrid assays reveal that p110 interacts through its TPR domain with the U4/U6-
specific 90K protein, indicating a specific role of the TPR domain in spliceosome recycling. On the 90K protein,
a short internal region (amino acids 416 to 550) suffices for the interaction with p110. Together, these data
suggest a model whereby p110 brings together U4 and U6 snRNAs through both RNA-protein and protein-
protein interactions.
Nuclear pre-mRNA splicing takes places in a large RNP
complex, the spliceosome, which is assembled in an ordered
multistep process. It consists of five small nuclear RNAs (the
U1, U2, U4, U5, and U6 snRNAs) and more than 100 proteins,
as recent proteomic analyses have determined (15, 16, 39). The
spliceosome shows characteristic dynamics during assembly
and splicing catalysis. For example, only the U2, U5, and U6
snRNAs participate in the catalytic center of the spliceosome,
whereas the U1 and U4 snRNAs play essential roles only
during the early assembly stages. After completion of the two-
step splicing reaction and the release of mRNA and lariat
products, the spliceosome disassembles into its components.
Before entering a new cycle, at least some the components
presumably must be reactivated. However, very little is known
about this recycling phase of the spliceosome cycle.
The U4, U5, and U6 snRNAs enter the prespliceosome in
the form of the 25S U4/U6.U5 tri-snRNP but are released
from the spliceosome in their singular forms, the U4 and U6
snRNPs. These interact with each other to regenerate the
U4/U6 di-snRNP, in which the two snRNAs are stably base
paired (see Fig. 6C). The addition of the U5 snRNP generates the
U4/U6.U5 tri-snRNP, which is integrated into the spliceosome.
During each spliceosome cycle, the participating snRNAs un-
dergo extensive structural rearrangements governed by specific
protein factors (for reviews, see references 7, 27, 28, and 33).
Regarding the molecular organization of the mammalian
U4/U6 snRNP, a hierarchical assembly pathway has been dem-
onstrated; this pathway also is conserved in the related U4atac/
U6atac snRNP of the minor spliceosome (24). Of the five
specific protein components, the 15.5K protein initially recog-
nizes the loop region of the U4 5 stem-loop (23), followed by
binding of the 61K protein. The subsequent integration of the
20K/60K/90K protein heterotrimer requires an intact U4/U6
stem II structure. In addition, the U4 snRNA is associated with
the canonical Sm heptamer core, the U6 snRNA with the
corresponding LSm heptamer (1, 21).
Only recently a 110-kDa protein (called p110 hereafter) has
been identified in the mammalian system which is required for
recycling of the U4/U6 snRNP from singular U4 and U6
snRNPs (3). In addition, p110 was detected in the U6atac
snRNP and found it to function in recycling of the U4atac/
U6atac snRNP (8). The human p110 protein (also referred to
as SART3) had originally been characterized as a nuclear
protein copurifying with U6 snRNA capping activity (14, 31). It
associates only transiently with U6 snRNA, since it can be
detected in the U6 and U4/U6 snRNPs but is absent from both
the U4/U6.U5 tri-snRNP and the spliceosome. p110 is func-
tionally related to the yeast splicing factor Prp24 (30), which
has been demonstrated to function in U4/U6 RNA annealing
and U4/U6 snRNP recycling (11, 28, 36). It is concentrated in
the Cajal bodies, although it is also present in the nucleoplasm,
suggesting that Cajal bodies represent the cellular site of
U4/U6 snRNP recycling (34).
The domain structure of the human U6-p110 protein con-
sists of a large N-terminal region with at least seven tetratri-
copeptide repeat (TPR) motifs, two RNA recognition motifs
(RRMs) in the C-terminal half of U6-p110, and a stretch of 10
highly conserved amino acids at the C terminus (3, 26). A
splice variant of the human protein has been reported as a
full-length cDNA (AF 387506) (19) which arises through the
usage of a different 5 splice site in exon 7; this usage is
expected to result in a truncated protein carrying only three of
the seven TPR motifs.
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The 34-amino-acid TPR domain provides a structural unit of
two antiparallel  helices that assemble to a platform for spe-
cific protein-protein interactions (reviewed in reference 6).
This function is supported by the determination of the struc-
ture of the Ser/Thr phosphatase PP5 protein (9). The domain
present in p110 (and many other RNA-processing factors)
deviates slightly from the TPR consensus domain and has been
referred to as half a TPR (HAT) (25) or the crooked-neck-like
TPR domain (22, 38). The TPR-related pentatricopeptide re-
peat motifs and the HEAT, armadillo, and ankyrin repeats are
all members of a large family of tandemly arranged helical
repeat units (13, 32).
The p110 domain organization is conserved in many other
eukaryotes, including Caenorhabditis elegans, Arabidopsis thali-
ana, Schizosaccharomyces pombe, and Drosophila melanogaster
(3, 26); of the orthologues, only the well-known yeast Prp24
protein deviates from this domain organization, in that it lacks
the entire N-terminal half with the TPR domain. Therefore, we
were particularly interested in the possible role of the con-
served TPR domain in U4/U6 snRNP formation and recycling.
In this study, we have mapped the domains of p110 required
for specific snRNA binding, U4/U6 snRNP recycling activity,
and protein-protein interaction. In particular, we identified a
novel interaction of p110 with the U4/U6 snRNP-specific 90K
protein. We further demonstrate that under recycling condi-
tions, p110 functions as an essential splicing factor. Our study
yields new functional insights into how both RNA-protein and
protein-protein contacts contribute to U4/U6 snRNP assem-
bly.
MATERIALS AND METHODS
RNA analysis. RNAs were separated by electrophoresis in denaturing polyac-
rylamide-urea gels (8% acrylamide, 0.42% bisacrylamide, 50% urea; Tris-borate-
EDTA buffer) and visualized by silver staining or Northern blot analysis as
previously described (2). Digoxigenin (DIG)-labeled probes directed against
human U4 and U6 snRNAs were obtained by PCR with PCR DIG labeling mix
(Roche), M13 forward and reverse primers, and SP6-U4 (37) or SP6-U6 (5) as
a template, respectively.
Expression and purification of recombinant p110 protein and mutant deriv-
atives, Coomassie blue staining, and Western blotting. Full-length His6-p110
protein was expressed as described previously (3). For the glutathione S-trans-
ferase (GST) fusion of the protein, the GST open reading frame and the p110
coding sequence were amplified from pAcGHLT-A/p110nrb (14) and cloned
between the RsrII and XhoI sites of vector pFASTBAC HTa (Invitrogen Life
Technologies). The protein was expressed by using the Bac-To-Bac baculovirus
expression system (Invitrogen) as described previously (3).
The following shortened forms of the p110 open reading frame (NM_014706)
were constructed by PCR methods that introduced restriction sites and termi-
nation codons with the primers: C, C10, N, AF 387506, and RRM 1-2 (see
Results). The PCR products were cloned into vector pFASTBAC HTa, replacing
the first methionine with the N-terminal His tag of the vector. Recombinant
baculovirus for protein expression in SF21 cells was obtained by using the
Bac-to-Bac baculovirus expression system. For purification of recombinant p110
mutant derivatives, cytoplasmic and nuclear extracts from infected SF21 cells
were prepared (10, 18). Proteins were affinity selected under native conditions on
Ni-nitrilotriacetic acid–agarose (QIAGEN), eluted with 250 mM imidazole, and
dialyzed against buffer D (10). Proteins were separated in a sodium dodecyl
sulfate (SDS)–8% polyacrylamide gel and analyzed by Coomassie blue staining
or Western blotting with a polyclonal anti-p110 antibody (3). Proteins were
transferred to a Hybond enhanced chemiluminescence nitrocellulose membrane
(Amersham Pharmacia Biotech), immunostained with anti-p110 antiserum (1:
2,000 dilution) and anti-rabbit antibody–peroxidase (Roche; 1:20,000 dilution),
and detected by enhanced chemiluminescence.
p110 immunodepletion from HeLa cell nuclear extracts. For immunodeple-
tion of p110 from HeLa cell nuclear extracts, 200 l of packed protein A–Sepha-
rose CL-4B (Amersham) was equilibrated in buffer N100 (50 mM Tris-HCl [pH
8.0], 100 mM NaCl, 0.05% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM
dithiothreitol) and incubated with rotation overnight at 4°C with 200 l of
polyclonal anti-p110 antiserum and 200 l of buffer N100. Beads then were
washed five times with 1 ml of buffer N100 each time, followed by the addition of
nuclear extract (4C Biotec, Seneffe, Belgium) and incubation at 4°C for 1 h (450
l of extract per 100 l of packed beads). This depletion step was repeated twice.
As a control, mock-depleted HeLa cell nuclear extracts were prepared in parallel
without antiserum.
Analysis of RNA binding of p110 by coimmunoprecipitation. Total RNA was
purified from 400 l of HeLa cell S100 extract and incubated with 2.5 g of
recombinant full-length p110 protein or the same molar amount of the mutant
derivatives for 1 h at 30°C in a 250-l reaction mixture (0.5 mM ATP, 20 mM
creatine phosphate, 4.5 mM MgCl2, 50 mM KCl, and 80 U of RNasin [Promega]
in buffer D). After the addition of 200 l of buffer N100, p110 complexes were
immunoprecipitated with immobilized anti-p110 antibodies. Coprecipitated
RNAs were isolated after heating of the beads for 10 min at 80°C in proteinase
K buffer (100 mM Tris-HCl [pH 8.0], 12.5 mM EDTA, 150 mM NaCl, 1% SDS)
and were analyzed as described above.
In vitro splicing under recycling conditions in U4/U6 snRNP recycling assays.
Twofold reactions were prepared as described before (4, 17) with 30 l of HeLa
cell nuclear extract, mock-depleted extract, p110-immunodepleted extract, or
p110-depleted extract supplemented with baculovirus-expressed recombinant
p110 protein (500 ng per reaction). As a splicing substrate, 32P-labeled in vitro-
transcribed MINX pre-mRNA (40) was added (10 ng per 25-l reaction mixture,
corresponding to 1 splicing substrate); for 5- and 10-fold excesses, additional
unlabeled MINX pre-mRNA was added to final concentrations of 100 and 200
ng, respectively, per 25-l reaction mixture. Splicing was performed at 30°C, and
aliquots were taken after 45 and 90 min. After proteinase K treatment, RNAs
were prepared by phenolization, followed by fractionation in a denaturating 8%
polyacrylamide gel and autoradiography. Splicing efficiencies were quantitated
by using TotalLabSoftware (Nonlinear Dynamics Limited).
U4/U6 snRNP recycling assays were performed as described before (3). For
testing of the p110 mutant derivatives, p110-depleted HeLa cell nuclear extracts
were supplemented with 500 ng (per 25-l reaction mixture) of recombinant
p110 protein or the same molar amount of the mutant derivatives. In vitro
splicing was performed under recycling conditions (10-fold excess of MINX
splicing substrate) for 60 min at 30°C, and the entire reaction was fractionated by
CsCl density gradient centrifugation as described previously (20) with a CsCl-
buffer D solution at a density of 1.55 g/ml and containing 15 mM MgCl2. A total
of 10 fractions were obtained, and fractions 2 and 3 (free U4), 4 and 5 (U4/U6),
and 9 and 10 (free U6) were pooled. RNA was purified and analyzed in a
denaturing 8% polyacrylamide gel, followed by Northern hybridization with
DIG-labeled U4- and U6-specific probes.
Yeast two-hybrid and in vitro interaction assays. Protein-protein interactions
were assayed by using the Matchmaker-III two-hybrid system (Clontech). The
open reading frames of the U4/U6-specific 15.5K, 61K, 20K, 60K, and 90K
proteins as well as the full-length p110 protein, the p110 mutant derivatives N
and C, and the splice variant AF 387506 were cloned into vectors pGBKT7 and
pGADT7 (Clontech). The sequences encoding the full-length 90K protein and
truncated versions containing amino acids 1 to 442, 1 to 309, 1 to 194, 195 to 683,
303 to 683, 416 to 683, 416 to 550, and 551 to 683 were introduced into vector
pGADT7. After cotransformation of the constructs into yeast host strain AH109
by the lithium acetate method, cotransformants were selected for 5 days at 30°C
on minimal synthetic dropout medium lacking the amino acids leucine and
tryptophan. For assaying protein-protein interactions, cotransformants were rep-
lica plated on minimal synthetic dropout medium lacking leucine, tryptophan,
and histidine and, for a more stringent selection, also lacking adenine. As pos-
itive controls, vectors pGADT7-T and pGBKT7-53 (Clontech) containing simian
virus 40 large T antigen and p53 coding sequences, respectively, were used, and
empty vectors served as negative controls.
For immunoprecipitation assays, the coding sequences of the 90K and 60K
proteins were in vitro transcribed with T7 RNA polymerase from the pGBKT7
constructs and translated with 35S-labeled methionine by using a TNT coupled
reticulocyte lysate system (Promega). A total of 15 l of translation reaction
mixture was incubated for 2 h at 4°C in buffer N100 supplemented with 5 mM
MgCl2 and 50 mM KCl or in buffer N100 supplemented with 500 ng of baculo-
virus-expressed full-length p110 protein. Complexes formed were precipitated
with p110 antibodies prebound to protein A-Sepharose, followed by seven
washes with 0.75 ml each of buffer N100. The bound proteins were eluted by being
heated in protein sample buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10%
glycerol, 0.005% bromphenol blue, 5% -mercaptoethanol), fractionated by
SDS-polyacrylamide gel electrophoresis (PAGE), and visualized by autoradiog-
raphy.
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For assaying protein-protein interactions by GST pull-down assays, 90K mu-
tant proteins were in vitro translated with the addition of 35S-labeled methionine
by using a TNT T7 quick coupled transcription-translation system (Promega)
according to the manufacturer’s instructions. For each reaction, 1 g of recom-
binant GST-p110 or a comparable molar amount of GST was added together
with 100 l of reaction buffer (20 mM HEPES-KOH [pH 7.5], 100 mM NaCl,
0.01% NP-40, 1 mM dithiothreitol). Glutathione–Sepharose 4 M beads (Amer-
sham) were blocked for 2 h in reaction buffer supplemented with 1 g of bovine
serum albumin/l, 200 ng of tRNA/l, and 200 ng of glycogen/l, washed in
reaction buffer, and added to the proteins. After 1 h of incubation with head-
over-tail rotation at room temperature, the beads were washed extensively with
reaction buffer. The bound proteins were eluted by being heated in protein
sample buffer, fractionated by SDS-PAGE, and visualized by autoradiography.
RESULTS AND DISCUSSION
p110 domain analysis shows that C-terminal RRMs are
sufficient for specific U6 snRNA binding. To delineate the
domain structure of p110, we constructed a series of p110
mutant derivatives (Fig. 1; see Fig. 6B for a summary). Each
carries an N-terminal His6 tag and was expressed and purified
from baculovirus-transfected SF21 cells. Samples were ana-
lyzed after denaturing PAGE by Coomassie blue staining and
Western blotting (Fig. 1). In addition to wild-type protein p110
(amino acids 2 to 963), p110 mutant derivatives C, C10, N,
and RRM 1-2 were expressed. p110 C (amino acids 2 to 688)
carries the entire TPR domain, including the putative nuclear
localization signal region, but not the two RRMs and the
C-terminal 10 amino acids. In p110 C10 (amino acids 2 to
951), only the C-terminal 12 amino acids are missing; 10 of
these are highly conserved (amino acids 952 to 961). p110 N
(amino acids 537 to 963) lacks the entire N-terminal TPR
domain but contains the putative nuclear localization signal
region, the two RRMs, and the C-terminal 10 amino acids. In
addition, a minimal derivative that includes only the two
RRMs (p110 RRM 1-2) was generated. Finally, we expressed
a natural splice variant, AF 387506 (see above), which is trun-
cated within the fourth TPR motif and contains amino acids 2
to 350, followed by 14 additional amino acids, RSTTESKGF
GFICT.
We tested the RNA binding specificity of these p110 deriv-
atives by incubating each of them with total RNA prepared
from an S100 extract and analyzing bound RNAs after immu-
noprecipitation with anti-p110 antibodies by using both silver
staining (Fig. 2A) and Northern blotting with a probe specific
for U4 and U6 snRNAs (Fig. 2B). Binding to U4 snRNA
served as a negative control, since the total RNA preparation
had been heat denatured before binding and the U4/U6
snRNA duplex is not stable under these conditions (data not
shown). Our polyclonal anti-p110 antibody was able to recog-
nize these different p110 derivatives with comparable efficien-
cies in solution (data not shown). The results showed that only
two of the mutant proteins, p110 C10 and p110 N, were able
to bind specifically U6 snRNA from total S100 extract RNA
and with efficiencies similar to that of the wild-type protein. In
contrast, p110 C and the splice variant AF 387506 did not
bind U6 snRNA detectably. The minimal construct with the
two RRMs, p110 RRM 1-2, associated with U6 snRNA only at
a very low efficiency.
We conclude that the RRMs are required for U6 snRNA
binding; for efficient RNA binding, additional sequences flank-
ing the RRMs are important (compare the U6 binding activi-
ties of p110 RRM 1-2 and p110 N). However, the conserved
C-terminal 10 amino acids and the TPR domain play no es-
sential role in U6 snRNA binding (compare p110 wild-type,
p110 C10, and p110 N).
Role of the p110 TPR domain in U4/U6 snRNP recycling. To
establish in vitro recycling conditions, 32P-labeled MINX pre-
mRNA (40) was spliced in vitro with a normal pre-mRNA
concentration (10 ng per 25-l reaction mixture) or 5- and
10-fold higher concentrations (Fig. 3). At the normal MINX
pre-mRNA concentration, the MINX pre-mRNA:U4:U6 mo-
lar ratio corresponds to 1:5:10. In each case, reactions were
carried out with three different nuclear extracts: mock-de-
pleted extracts, p110-immunodepleted extracts, and p110-de-
pleted extracts complemented with 500 ng of baculovirus-ex-
pressed recombinant p110 protein per 25-l reaction mixture.
Two time points (45 and 90 min) were assayed, and splicing
efficiencies were quantitatively determined (expressed as the
FIG. 1. Baculovirus expression of human U6-p110 mutant derivatives. The expression of wild-type U6-p110, splice variant AF 387506, and
mutant proteins C, C10, RRM 1-2, and N was detected by Coomassie blue staining (left panel) and by Western blotting (right panel).
Molecular mass markers (in kilodaltons) are given on the left.
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FIG. 2. Mutational analysis of p110 protein-U6 snRNA binding in vitro. Total RNA from a HeLa cell S100 extract was incubated with
recombinant full-length p110 protein or an equimolar amount of splice variant AF 387506 or mutant derivative C, C10, RRM 1-2, or N. Ten
percent of the RNA input was analyzed in parallel (input lanes). Control reactions were carried out in the absence of added p110 protein (control
lanes). The p110-RNA complexes formed were immunoprecipitated with anti-p110 antibodies, and the coprecipitated RNAs were analyzed by
denaturing gel electrophoresis and detected by silver staining (A) or by Northern blotting with U4- and U6-specific probes (B). The line in panel
B separates autoradiograms from two separate experiments. The mobilities of the U1, U2, U4, U6, and 5S RNAs are marked on the left. Lanes
M, pBR322/HpaII marker fragments (A) and DIG marker V (Roche) (B). The arrows indicate the positions of the U4 and U6 snRNAs.
FIG. 3. U6-p110 is required for splicing in vitro only under recycling conditions. MINX pre-mRNA was spliced in vitro at concentrations of 10
ng (1; lanes 2 to 7), 50 ng (5; lanes 8 to 13), and 100 ng (10; lanes 14 to 19) per 25-l reaction in mock-depleted nuclear extracts (lanes 2,
3, 8, 9, 14, and 15), p110-depleted nuclear extracts (lanes 4, 5, 10, 11, 16, and 17), and p110-depleted nuclear extracts complemented with 500 ng
of recombinant p110 (lanes 6, 7, 12, 13, 18, and 19). Input MINX pre-mRNA is shown in lane 1. Assays were carried out for 45 and 90 min. The
positions of pre-mRNA, spliced product mRNA, and the first-exon intermediate are indicated on the left.
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ratio of spliced mRNA to pre-mRNA). Under normal condi-
tions, the MINX pre-mRNA was spliced efficiently and at
comparable levels in the three extracts: splicing efficiencies at
the 90-min time point in mock-depleted, p110-depleted, and
p110-complemented extracts were 35, 34, and 32%, respec-
tively (Fig. 3, left panel, lanes 3, 5, and 7). In contrast, at a
fivefold higher pre-mRNA concentration (Fig. 3, middle
panel), we consistently observed a large difference between the
splicing activities in mock- and p110-depleted extracts (15 ver-
sus 6%); the addition of recombinant p110 protein fully re-
stored the splicing activity level of the mock-depleted extract
(to 18%), demonstrating that the splicing defect under these
conditions is due to the specific depletion of p110 (lanes 9, 11,
and 13). Finally, at a 10-fold higher pre-mRNA concentration
(Fig. 3, right panel), splicing activity was almost undetectable
in the p110-depleted extract (2% compared to 11% in the
mock-depleted extract) but could be efficiently complemented
by recombinant p110 protein to the level of the mock-depleted
extract (15%) (lanes 15, 17, and 19).
In summary, these findings demonstrate that p110 is re-
quired as a splicing factor only under conditions when rela-
tively high levels of pre-mRNA are turned over, consistent with
recent evidence that p110 is involved in U4/U6 snRNP recy-
cling.
To identify which p110 domains are required for U4/U6
snRNP recycling, we tested each of the p110 derivatives under
these conditions in a recently described in vitro complementa-
tion assay of U4/U6 snRNP recycling (3) (Fig. 4A shows a
schematic representation). Briefly, in vitro splicing was carried
out with an excess of pre-mRNA substrate and a p110-immu-
nodepleted nuclear extract (Fig. 4B); a mock-depleted nuclear
extract served as a control. After the splicing incubation, the
base pairing status of U4 and U6 snRNAs was assessed
through CsCl density gradient centrifugation (Fig. 4C).
Thereby, free U4 (fractions 2 and 3) and U6 (fractions 9 and
10) were separated from the U4/U6 snRNP (fractions 4 and 5);
the distribution of U4 and U6 snRNAs across the gradient was
detected by Northern hybridization with U4- and U6-specific
probes. p110 depletion resulted in a complete dissociation of
the U4/U6 snRNP (Fig. 4C, compare lanes 4 to 6 with the
FIG. 4. Mutational analysis of p110 protein-U4/U6 snRNP recycling activity. (A) Schematic representation of the U4/U6 snRNP recycling assay
(see the text and reference 3). NE p110, p110-depleted nuclear extract. (B) p110 immunodepletion of nuclear extracts. Aliquots of normal nuclear
extracts (input lane) and nuclear extracts after mock depletion (NE mock lane) and after p110 depletion (NE p110 lane) were analyzed by
Western blotting with anti-p110 antibodies. (C) U4/U6 snRNP recycling assay of p110 mutant derivatives. Splicing reactions were carried out with
mock-depleted nuclear extracts (lanes 1 to 3), p110-depleted nuclear extracts (lanes 4 to 6), and p110-depleted nuclear extracts complemented with
wild-type U6-p110 (lanes 7 to 9), splice variant AF 387506 (lanes 10 to 12), or mutant derivative C (lanes 13 to 15), C10 (lanes 16 to 18), RRM
1-2 (lanes 19 to 21), or N (lanes 22 to 24). After CsCl gradient fractionation, the distribution of postspliceosomal U4, U4/U6, and U6 snRNPs
was analyzed by Northern blotting with U4- and U6-specific probes and pooled fractions 2 and 3 (free U4), 5 and 6 (U4/U6), and 9 and 10 (free
U6). The positions of the U4 and U6 snRNAs are marked on the right.
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FIG. 5. p110 interacts through its TPR domain with a C-terminal region (amino acids 416 to 550) of the U4/U6 snRNP-specific 90K protein.
(A) Yeast two-hybrid assay of interactions between p110 and U4/U6-specific proteins. Yeast strain AH109 was transformed with plasmid
pGBKT7-15.5K, pGBKT7-20K, pGBKT7-60K, pGBKT7-61K, or pGBKT7-90K in combination with plasmid pGADT7-p110. As controls, co-
transformations were done with pGADT7-p110 and plasmid pGBKT7 as well as with plasmid pGADT7-T (containing simian virus 40 large T
antigen) and plasmid pGBKT7-53 (containing p53). Protein-protein interactions were assayed by selection on minimal synthetic dropout medium
lacking leucine, tryptophan, histidine, and adenine for 3 days at 30°C. (B) Yeast two-hybrid assay of interactions between p110 mutant derivatives
and the U4/U6-specific 90K protein. Yeast strain AH109 was transformed with plasmid pGADT7-p110, pGADT7-N, pGADT7-C, or
pGADT7-AF 387506 (AF) in combination with plasmid pGBKT7-90K. As controls, cotransformations were done with plasmid pGBKT7 or with
plasmids pGADT7 and pGBKT7-90K. Selection was done for 3 days at 30°C on minimal synthetic dropout medium lacking leucine, tryptophan,
and histidine (SD-LWH medium). (C) Yeast two-hybrid assay of interactions between p110 and U4/U6-specific 90K protein mutant derivatives.
Yeast strain AH109 was transformed with plasmid pGADT7, pGADT7-p110, or pGADT7-C. In addition, plasmid pGBKT7-90K or pGBKT7
constructs containing various regions of the 90K protein (amino acids 1 to 442, 1 to 309, 1 to 194, 303 to 683, 195 to 683, 195 to 683, 416 to 550,
and 551 to 683) were cotransformed. Interactions were assayed for 3 days at 30°C on SD-LWH medium. wt, wild type. (D) Mutational analysis
of the p110-90K protein interaction by GST pull-down assays. 35S-labeled full-length 90K protein and mutant derivatives containing amino acids
416 to 683, 416 to 550, and 551 to 683 were incubated with GST-p110 protein, followed by GST pull-down assays. Coprecipitated proteins were
fractionated by SDS-PAGE and visualized by autoradiography. For each assay, 10% of the input (lanes I) and the precipitated material (lanes
GST) are shown; control reactions contained only GST protein (lanes Ctr). The mobilities of the 90K full-length and mutant proteins are marked
on the left and right.
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mock-depleted reaction in lanes 1 to 3). In an analysis of the
complementation reactions, only the wild-type protein (Fig.
4C, lanes 7 to 9) and p110 C10 (lanes 16 to 18) were active in
restoring the U4/U6 base-paired status. Neither p110 C (Fig.
4C, lanes 13 to 15), RRM 1-2 (lanes 19 to 21), p110 N (lanes
22 to 24), nor the splice variant AF 387506 (lanes 10 to 12)
exhibited significant U4/U6 snRNP recycling activity above the
level of the uncomplemented reaction (lanes 4 to 6).
In conclusion, U4/U6 snRNP recycling activity in vitro re-
quires both the N-terminal TPR domain and the C-terminal
RRMs; however, the conserved C-terminal 10 amino acids are
not essential (see Fig. 6B for a summary). These conclusions
were surprising in light of recent studies with the yeast system
that have revealed roles of the highly conserved C-terminal 10
amino acids in the interaction of Prp24 with the U6-specific
LSm heptamer and in U4/U6 snRNP formation (26, 29). In
contrast, the functional in vitro assays of the human protein
reported here provided no evidence for an essential role of this
C-terminal sequence. In particular, deletion of the C-terminal
10 amino acids did not detectably affect in vitro U4/U6 recy-
cling activity (Fig. 4C). Possible explanations for this apparent
discrepancy are (i) that there are some minor differences in the
functional contributions of individual domains between the
two systems, (ii) that our in vitro assay is not sensitive enough
to detect the contribution of the LSm-p110 interaction, and
(iii) that there are more built-in redundancies in the mamma-
lian system than in the yeast system.
The inactivity of p110 C in recycling can be explained by its
U6 snRNA binding defect (Fig. 2). More importantly, the
inactivity of p110 N clearly dissects the U6 snRNA binding
and U4/U6 snRNP recycling functions. Thus, the TPR domain
fulfills a specific role in the U4/U6 recycling process, presum-
ably through mediating protein-protein interactions (see be-
low). Finally, the natural splice variant AF 387506, which re-
tains only part of the TPR domain, was inactive in U4/U6
snRNP recycling.
p110 interacts through its TPR domain with a C-terminal
region (amino acids 416 to 550) of the U4/U6 snRNP-specific
90K protein. To investigate the role of the N-terminal TPR
domain of p110, we performed yeast two-hybrid assays with the
U4 and U4/U6 snRNP-specific 15.5K, 61K, 20K, 60K, and 90K
proteins (Fig. 5A). Of these proteins, only the 90K protein
showed an interaction with the full-length p110 protein. The T
antigen-p53 interaction served as a positive control; cotrans-
formation with pGBKT7 and pGADT7-p110 served as a negative
control. Independently, we also twice recovered in a genomic
yeast two-hybrid screen a full-length clone of the 90K protein,
confirming the significance of this interaction (data not shown)
and consistent with recent fluorescence resonance energy transfer
measurements in HeLa cells (D. Stanek and K. M. Neugebauer,
submitted for publication).
The p110-90K protein interaction depended on the 90K
protein component and was specific, since p110 N gave a
negative result; in contrast, both p110 C and the natural
splice variant AF 387506 gave a positive result for the 90K
protein interaction (Fig. 5B). The specific association of p110
and the U4/U6-specific 90K protein was confirmed by a coim-
munoprecipitation assay (data not shown). An in vitro-trans-
lated 90K protein could—after incubation with recombinant
p110 protein—be efficiently coimmunoprecipitated with anti-
p110 antibodies; the specificity of the interaction was demon-
strated by the fact that an in vitro-translated 60K protein,
another U4/U6-specific protein, was not coimmunoprecipi-
tated.
Mutational analysis of the 90K protein (Fig. 5C) showed in
two-hybrid assays that the amino-terminal half of the 90K
protein did not interact with p110 (see constructs with amino
acids 1 to 442, 1 to 309, and 1 to 194). In contrast, C-terminal
fragments of the 90K protein were positive for the p110 inter-
action (see constructs with amino acids 303 to 683 and 194 to
683). This interaction domain of the 90K protein could be
further shortened to C-terminal amino acids 416 to 683. Fi-
nally, this region was subdivided into two halves, amino acids
416 to 550 and 551 to 683; only the first half was able to interact
with p110, whereas the latter half was negative in this assay.
When the p110 mutant derivative C was used instead of
full-length p110, identical results were obtained, consistent
with the TPR domain mediating the interaction between p110
and the 90K protein.
These conclusions from two-hybrid assays were subsequently
confirmed by in vitro GST pull-down assays (Fig. 5D). GST-
p110 (full length) efficiently interacted with the in vitro-trans-
lated, 35S-labeled 90K protein as well as the two 90K protein
derivatives with C-terminal amino acids 416 to 683 and 416 to
550 but not the 90K protein derivative with C-terminal amino
acids 551 to 683.
In summary, we conclude that the C-terminal part of p110
containing two RRMs and the highly conserved C-terminal
sequence are dispensable for the 90K protein interaction. In
contrast, the N-terminal TPR domain and the three N-termi-
nal HAT motifs alone appear to be sufficient for 90K protein
binding. As no other protein motifs are predicted in this N-
terminal part of p110, the results strongly suggest that the
HAT motifs mediate the specific interaction with the 90K
FIG. 6. Summary of the domain organization and mutant derivatives of human U4-90K and U6-p110 proteins and model of U4/U6 snRNP
recycling. (A) Human U4-90K wild-type protein (683 amino acids [aa]) and mutant derivatives containing amino acids 1 to 442, 1 to 309, 1 to 194,
195 to 683, 303 to 683, 416 to 683, 416 to 550, and 551 to 683 are schematically represented. The dark gray boxes indicate the N-terminal PWI
domain. The abilities of 90K wild-type protein and mutant derivatives to interact with p110 in two-hybrid assays (Fig. 5C) and GST pull-down
assays (Fig. 5D) are shown on the right ( or ). Regions sufficient for the U4-90K or U6-p110 protein interactions are marked by the bracket
and the arrow. (B) The following activities of p110 protein, of mutant derivatives N, C, C10, and RRM 1-2, and of splice variant AF 387506
are summarized: U6 snRNA binding (Fig. 2), U4/U6 snRNP recycling (Fig. 4), and 90K protein interactions (Fig. 5). The p110 domain structure
is schematically represented (RRMs, striped boxes; HAT or TPR domain, white boxes; conserved C-terminal region, black boxes). , activity like
that of full-length p110; /, low activity above the background; , no activity; ND, not determined. For comparison, the domain organization
of the p110-related Prp24 protein from the yeast S. cerevisiae is also shown. (C) Model of U4/U6 snRNP recycling and p110 interactions. The model
of the U4 snRNP is that described by Nottrott et al. (24).
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protein. There seems to be some redundancy in the interac-
tion, since the number of TPR motifs varies at least between
three and seven in the known orthologues (3, 26). These data
would also be consistent with our finding that the three N-
terminal TPR motifs present in the splice variant AF 387506
appear to suffice for the 90K protein interaction (Fig. 5B). The
latter finding raises the interesting question as to whether the
splice variant may act as a negative regulator of p110 function,
competing for the 90K protein interaction but lacking the
RNA binding and recycling functions.
In the 90K protein, a short internal region near the C ter-
minus (amino acids 416 to 550) that suffices for the p110
interaction was identified (Fig. 6A and B show a summary of
the interaction data). This region provides a novel bridge be-
tween the U6 snRNA-bound p110 and the U4/U6-specific pro-
tein components and most likely plays an important role in
U4/U6 snRNP assembly (Fig. 6C). In addition, the p110 inter-
action defines a new interface of the 90K protein, different
from the amino-terminal PWI domain of the 90K protein
(amino acids 3 to 76), which recognizes nucleic acids (35), and
different from the central region, which mediates the interac-
tion with the 60K protein (12). We also note that the 90K
protein—within the 20K/60K/90K complex—contacts the U6
snRNA in the stem II region (24), and this event may stabilize
the newly formed U4/U6 base-paired structure.
Does the fact that the entire TPR domain is absent in the
yeast Prp24 protein reflect a yeast-specific feature of the
U4/U6 snRNP recycling mechanism? This scenario appears to
be unlikely, because—except for Prp24 and p110—all known
protein constituents of the U4/U6 snRNP are highly conserved
between the yeast and mammalian systems. As discussed by
Rader and Guthrie (26), the 90K protein-TPR domain inter-
action may in fact be conserved in Saccharomyces cerevisiae,
but with the TPR domain residing in a polypeptide other than
Prp24. This suggestion is supported by the fact that the C
terminus of the 90K protein, which interacts with p110 in the
human system, is conserved in the yeast Prp3 protein.
How do these findings change our model of the U4/U6
snRNP assembly pathway? In contrast to the yeast protein, the
mammalian p110 protein carries only two RRMs homologous
to the highly conserved second and third RRMs of Prp24. As
proposed by Rader and Guthrie (26), the additional RRMs of
Prp24, 1 and 4, may recognize U4 snRNA and thereby pro-
mote the U4/U6 interaction. Perhaps this U4 interaction has
shifted from an RNA-protein interaction (such as in yeast
Prp24 RRMs 1 and 4 with the U4 snRNA) in the mammalian
and other systems to a protein-protein interaction (p110 TPR
domain with the 90K protein). What makes p110 leave the
reassembled U4/U6 snRNP? Most likely this signal is provided
by the U5 snRNP association, which results in U4/U6.U5 tri-
snRNP formation. It will be important in further studies to
identify this signal, with the aim of fully describing the struc-
tural rearrangements that accompany the recycling and assem-
bly of functional snRNPs.
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